Respiratory Dysfunction in Sleep Apnea Associated with Quetiapine

Abstract

Quetiapine is an atypical antipsychotic with good tolerability, but has recently been associated with respiratory dysfunction. The aim of this work is to report on moderate to severe respiratory dysfunction after normal oral doses of quetiapine in two obese patients with sleep apnea syndrome (SAS). In the first case, acute respiratory failure and coma occurred after a single normal oral dose of quetiapine in combination with lorazepam (although even higher doses of lorazepam alone were tolerated) in a patient with previously unknown SAS. Intensive care treatment and mechanical ventilation led to full recovery. The second case was a patient with an operated obstructive SAS in which quetiapine was associated with nocturnal respiratory dysfunction and confusion. Respiratory function should be monitored when using quetiapine in patients with possible sleep apnea, particularly in obese patients and when given in combination with benzodiazepines.

References

• 1 Balit CR, Isbister GK, Hackett LP, Whyte IM. Quetiapine poisoning: a case series.  Ann Emerg Med. 2003;  42 751-758
• 2 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie, 6th edn.  Berlin: Springer. 2006;  307-309 , , 362-364
• 3 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management.  Lancet. 2000;  356 1255-1259
• 4 Fernandes PP, Macil WA. Death associated with quetiapine overdose.  Am J Psychiatry. 2002;  159 2114
• 5 Hustey FM. Acute quetiapine poisoning.  J Emerg Med. 1999;  17 995-997
• 6 Jabeen S, Pollo SI, Gerber DR. Acute respiratory failure with a single dose of quetiapine fumarate.  Ann Pharmacother. 2006;  40 559-563
• 7 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. et al . A method for estimating the probability of adverse drug reactions.  Clin Pharmacol Ther. 1981;  30 239-245
• 8 Pollak PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions.  Clin Pharmacol Ther. 2000;  68 92-97
• 9 Shelton PS, Barnett FL, Krick SE. Hyperventilation associated with quetiapine.  Ann Pharmacother. 2000;  34 335-337
• 10 Stahl SM. Essential psychopharmacology: the prescriber's guide. Cambridge: Cambridge University Press 2006
• 11 Stephan PL, Jaquenoud Sirot E, Mueller B, Eap CB, Baumann P. Adverse drug reactions following nonresponse in a depressed patient with CYP 2D6 deficiency and low CYP 3A4/5 activity.  Pharmacopsychiatry. 2006;  39 150-152
• 12 Strachan PM, Bernoff BA. Mental status change, myoclonus, electrocardiographic change, and acute respiratory distress syndrome induced by quetiapine overdose.  Pharmacotherapy. 2006;  26 578-582
• 13 The European Agency for the Evaluation of Medicinal Products . (European Medicines Agency E. ICH Topic E 2 A: Clinical safety data management: Definitions and standards for expedited reporting.  , CPMP/ ICH/377/95. 1995; 
• 14 Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.  J Psychopharmacol. 2007;  21 392-399
• 15 World Health Organization (WHO) . Uppsala Monitoring Centre-Definitions.  http://who-umc.org/defs.html

Correspondence